379 related articles for article (PubMed ID: 2760221)
1. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model.
Cadroy Y; Houghten RA; Hanson SR
J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221
[TBL] [Abstract][Full Text] [Related]
2. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
Cadroy Y; Horbett TA; Hanson SR
J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates.
Yokoyama T; Kelly AB; Marzec UM; Hanson SR; Kunitada S; Harker LA
Circulation; 1995 Aug; 92(3):485-91. PubMed ID: 7634464
[TBL] [Abstract][Full Text] [Related]
4. Nanosized aspirin-Arg-Gly-Asp-Val: delivery of aspirin to thrombus by the target carrier Arg-Gly-Asp-Val tetrapeptide.
Jin S; Wang Y; Zhu H; Wang Y; Zhao S; Zhao M; Liu J; Wu J; Gao W; Peng S
ACS Nano; 2013 Sep; 7(9):7664-73. PubMed ID: 23931063
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin.
Cadroy Y; Harker LA; Hanson SR
J Lab Clin Med; 1989 Oct; 114(4):349-57. PubMed ID: 2551985
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates.
Gruber A; Harker LA; Hanson SR; Kelly AB; Griffin JH
Circulation; 1991 Dec; 84(6):2454-62. PubMed ID: 1835678
[TBL] [Abstract][Full Text] [Related]
7. Recombinant leech antiplatelet protein prevents collagen-mediated platelet aggregation but not collagen graft thrombosis in baboons.
Schaffer LW; Davidson JT; Siegl PK; Gould RJ; Nutt RF; Brady SF; Connolly TM
Arterioscler Thromb; 1993 Nov; 13(11):1593-601. PubMed ID: 8218100
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons.
Cadroy Y; Maraganore JM; Hanson SR; Harker LA
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1177-81. PubMed ID: 1996320
[TBL] [Abstract][Full Text] [Related]
9. Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates.
Cadroy Y; Hanson SR; Harker LA
Arterioscler Thromb; 1993 Aug; 13(8):1213-7. PubMed ID: 8343496
[TBL] [Abstract][Full Text] [Related]
10. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of thrombus formation in vivo by novel antiplatelet agent.
Marzec UM; Kelly AB; Hanson SR; Lasslo A; Harker LA
Arteriosclerosis; 1990; 10(3):367-71. PubMed ID: 2140503
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model.
Imura Y; Stassen JM; Bunting S; Stockmans F; Collen D
Blood; 1992 Sep; 80(5):1247-53. PubMed ID: 1515641
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.
Kelly AB; Maraganore JM; Bourdon P; Hanson SR; Harker LA
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6040-4. PubMed ID: 1385867
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
15. A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.
Roussa VD; Stathopoulou EM; Papamichael ND; Englezopoulos CV; Rousouli KI; Trypou P; Moussis V; Tellis CC; Katsouras CS; Tsikaris V; Tselepis AD; Michalis LK
Platelets; 2011; 22(5):361-70. PubMed ID: 21158497
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates.
Cadroy Y; Hanson SR; Harker LA
Thromb Haemost; 1993 Oct; 70(4):631-5. PubMed ID: 8115989
[TBL] [Abstract][Full Text] [Related]
17. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist.
Kotzé HF; Lamprecht S; Badenhorst PN; van Wyk V; Roodt JP; Alexander K
Thromb Haemost; 1993 Oct; 70(4):672-5. PubMed ID: 8115994
[TBL] [Abstract][Full Text] [Related]
18. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K
Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742
[TBL] [Abstract][Full Text] [Related]
19. Antihemostatic and antithrombotic effects of monoclonal antibodies against von Willebrand factor in nonhuman primates.
Krupski WC; Bass A; Cadroy Y; Kelly AB; Harker LA; Hanson SR
Surgery; 1992 Aug; 112(2):433-9; discussion 439-40. PubMed ID: 1641780
[TBL] [Abstract][Full Text] [Related]
20. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon.
Hanson SR; Pareti FI; Ruggeri ZM; Marzec UM; Kunicki TJ; Montgomery RR; Zimmerman TS; Harker LA
J Clin Invest; 1988 Jan; 81(1):149-58. PubMed ID: 2961790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
